• Connect with Us at the CPS Annual Meeting & Vendor Expo

    May 2-4, Vice President – Implementations and Sales Support Ryen Brumbeloe and Sales Manager ­– Midwest Region Todd Hudnall will attend and exhibit at the Comprehensive Pharmacy Systems/Pharmacy Systems, Inc. (CPS) Annual Meeting & Vendor Expo in Indianapolis, IN. There, over 450 pharmacy decision makers will connect and gain insight into the latest industry news.… Read more »

  • Clinical Insights: April 16, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval Afinitor Disperz® (everolimus) – New Formulation and Indication Approval – April 10, 2018 – On April 10, 2018, the Food… Read more »

  • Ready to Network at the HCP 2018 Spring Hospital Pharmacy Conference

    Justin Rolling and Rhodie Smith are attending the Health Connect Partners (HCP) 2018 Spring Hospital Pharmacy Conference April 30 – May 2 in Atlanta and representing RxStrategies. Here, America’s most prestigious hospitals and health systems will come together to gain industry-leading insight and education and network through the two Reverse EXPO sessions. Be sure to… Read more »

  • Stay on Top of 340B with Split Billing

    RxStrategies recognizes the complexities of 340B program management and offers solutions to better ensure proper management and program compliance. With our Split Billing Solution, you can: Review prescription activity Flag eligible 340B dispenses Designate activity for proper replenishment Audit and report GPO, WAC and 340B With customized reporting, onsite audit support, order confirmations, pharmacy system… Read more »

  • Clinical Insights: April 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymfiTM (efavirenz, lamivudine and tenofovir disoproxil fumarate) – March 22, 2018 – Mylan N.V. announced that it will introduce in the U.S. a third cost-saving HIV… Read more »

  • Clinical Insights: March 23, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval IlumyaTM (tildrakizumab-asmn) – New Drug Approval – March 21, 2018 – Sun Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved… Read more »

  • Integrated Solutions to Maintain Program Compliance

    There are many challenges organizations face when maintaining a compliant 340B Drug Pricing Program. At RxStrategies, we specialize in delivering integrated solutions to assist implementation and compliance.   Split Billing Provides end-to-end 340B program management and addresses its complexity by reviewing all prescription activity to flag eligible 340B dispenses.   CompliancePlus Streamlines workflow, quickly indemnifies… Read more »

  • Clinical Insights: February 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®… Read more »

  • Clinical Insights: February 5, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the… Read more »

  • Clinical Insights: January 22, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval BalcoltraTM (levonorgestrel and ethinyl estradiol and ferrous bisglycinate) – January 19, 2018 – Avion Pharmaceuticals, LLC, received approval of its new drug application (NDA) for the oral contraceptive… Read more »